Windtree Therapeutics Inc (WINT)

Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates

Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any...

Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space

Windtree is executing its corporate strategy to diversify its business with revenue and profit generating...

Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee

The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in...

Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate

Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a...

Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company

Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to...

Form 8-K - Current report

Form 8-K - Current report

Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting

The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock...

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals...

Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption

Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding...